BioCentury
ARTICLE | Finance

Autologous monetization

LPs flock to Athyrium's structured capital fund for life sciences/healthcare

May 27, 2013 7:00 AM UTC

While the equity markets have clear appetite for new biotech paper, the oversubscribed Athyrium Opportunities Fund L.P. shows investors are not turning a blind eye to alternative financing vehicles.

Athyrium Capital Managementand partnerNeuberger Bermanclosed the life sciences credit fund at $507 million last week. The size is well above the original target of $350 million...